D1EX34 Stock Price and Chart — BMFBOVESPA:D1EX34

Overview

Key facts today

DexCom, Inc. (DXCM) cut its 2024 revenue forecast to $4-$4.05 billion after a 36% post-market drop, citing weak Q2 sales, U.S. salesforce issues, and stiff competition.

DexCom responds to reduced outlook by enhancing sales integration and launching Stelo CGM, a non-prescription product, amid declining new users and revenue.

DexCom, Inc. experienced a significant drop of over 35% in premarket trading following the announcement of its quarterly results.

Analyze the impact Analyze the impact

About DexCom, Inc.

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.